Background: B490 (EudraCT# 2011-002564-24) is a randomized, phase 2b, noninferiority study investigating the efficacy and safety of first-line cetuximab plus cisplatin with/without paclitaxel (CetCis versus CetCisPac) in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Introduction
Globally, more than half a million people are diagnosed with squamous cell carcinoma of the head and neck (SCCHN) annually [1, 2] . Among them, patients with recurrent and/or metastatic SCCHN (R/M SCCHN) have the worst prognoses, with currently available first-line therapies yielding a median overall survival (OS) of <1 year [3, 4] , and a somewhat limited continuum of care (with only two effective lines of therapy) [5, 6] . Because approximately half of patients with newly diagnosed locoregionally advanced SCCHN develop recurrent disease within 5 years, and another 10% of all newly diagnosed patients present with metastases [7] [8] [9] , there is a critical need for novel therapeutic combinations to improve survival and quality of life for patients with R/M SCCHN.
The current first-line standard of care for patients with R/M SCCHN is the EXTREME regimen, which combines the antiepidermal growth factor receptor monoclonal antibody cetuximab with platinum-based chemotherapy (cisplatin or carboplatin) and 5-fluorouracil (5-FU) [4, 10] . Historically, R/M SCCHN was treated with single or double chemotherapy [11, 12] , until the addition of cetuximab to cisplatin plus 5-FU proved to be the first treatment to yield a significant survival benefit in patients compared with polychemotherapy alone [median OS: 10.1 versus 7.4 months, respectively; median progression-free survival (PFS): 5.6 versus 3.3 months, respectively] [4] . Notably, the EXTREME regimen is associated with somewhat high toxicity and is thus reserved for select patients who are fit enough to receive it. Indeed, 5-FU in particular is difficult to administer (requiring a central venous catheter for a continuous infusion) [13] and has been associated with life-threatening adverse events-especially cardiotoxicity-requiring close monitoring and can result in death in this frail patient population [14] .
Furthermore, although supported with category 1 evidence, the EXTREME regimen is not always selected by clinicians, especially in the United States, where instead a taxane is routinely paired with cisplatin-based chemotherapy in the first line [15] , and cetuximab monotherapy is thus given in the second line (a treatment sequence permitted per treatment guidelines, but not supported by category 1 evidence) [15] . Hence, there is an urgent need to characterize more tolerable systemic therapy alternatives to the landmark EXTREME regimen that yield similar efficacy benefits. Additionally, emerging immune checkpoint inhibitors nivolumab and pembrolizumab [16, 17] have demonstrated activity in the later-line setting and are currently being investigated as first-line treatment options. Such new agents may offer novel combination options and require an effective and tolerable systemic therapy backbone with which they can be combined.
One of the key considerations when treating patients with R/M SCCHN is the probability of tumor shrinkage and a treatment's expected overall response rate (ORR), and reducing tumor burden through palliative care (systemic treatment, radiation) may improve quality of life. One historical method for improving response rates has been to add a second or third cytotoxic agent [12, 18, 19] (including a taxane or a targeted agent [4, 12] ) to a proven treatment. Additionally, substitution of 5-FU in favor of a taxane in the EXTREME regimen may both improve EXTREME's ORR and its safety profile. Indeed, this approach also allows patients with contraindications to 5-FU to receive a three-agent regimen. Several studies have further demonstrated that the combination of cetuximab, cisplatin/carboplatin plus taxane yielded comparable or improved ORR and OS compared with the EXTREME regimen [although no head-to-head comparisons have been published, results from the ongoing randomized TPExtreme study (NCT02268695) will be informative once available] [13, 20, 21] . Indeed, cetuximab has activity in R/M SCCHN when combined only with a taxane (docetaxel or paclitaxel) [22] [23] [24] , and at least one preclinical study suggests a synergy between these two agents [25, 26] .
For these reasons, in the current study, we compared cetuximab plus cisplatin (CetCis) versus cetuximab plus cisplatin plus paclitaxel (CetCisPac) as first-line systemic therapy in a randomized, phase 2, noninferiority study of fit, EXTREME-eligible patients with R/M SCCHN. By selecting cetuximab plus cisplatin monotherapy as the backbone of both treatment arms, we leveraged their established, combined favorable safety profile and activity in R/M SCCHN and sought to determine whether the CetCis regimen yields noninferior PFS versus CetCisPac while also investigating other potential response and survival differences. 
Patients and methods

Trial design
Treatment
Cetuximab was administered on day 1 as a 2-h infusion of 400 mg/m 2 , followed by weekly 1-h infusions of 250 mg/m 2 . Cisplatin was given as a 1-h infusion of 100 mg/m 2 on day 1 of each 21-day cycle for a maximum of six cycles. In the CetCisPac comparator arm, the cisplatin dose decreased to 75 mg/m 2 . Paclitaxel was administered as a 3-h infusion of 175 mg/m 2 on day 1 of each 21-day cycle for a maximum of six cycles. Cetuximab maintenance therapy was given until disease progression or unacceptable toxicity. Unacceptable toxicity or disease progression led to termination of treatment.
Outcome assessments
The primary end point of the B490 study was PFS. Secondary end points included OS, ORR, safety, and identification of predictive and prognostic markers. PFS and ORR assessments were based on Response Evaluation Criteria In Solid Tumors (RECIST criteria, Version 1.1). The main efficacy end points were determined for the intent-to-treat (ITT) population, consisting of all randomized patients who received at least one treatment dose.
Please refer to the Supplementary Material, available at Annals of Oncology online, for details regarding eligibility criteria and statistical analysis.
Results
Patient population
Between September 2011 and September 2016, the B490 study enrolled 201 patients with R/M SCCHN ( Figure 1 ). The ITT population included 191 patients; baseline characteristics were reasonably balanced between treatment arms and are presented in Table 1 .
Overall, 61 (61.0%) and 60 (66.0%) patients had died in the CetCis and CetCisPac arms, respectively, and 48 (48.0%) and 51 (56.0%) patients died due to progression.
Efficacy
The B490 study evaluated survival end points for patients with R/M SCCHN receiving first-line cetuximab plus cisplatin with or without paclitaxel. In total, 164 PFS events were observed until the clinical data cutoff (30 June 2017) (87 events in the CetCis arm and 77 events in the CetCisPac arm). The upper boundary of the one-sided 90% CI for HR was 1.21 and thus below the pre-specified noninferiority margin of 1.4. The median PFS was 6 versus 7 months, respectively (HR ¼ 0.99; 95% CI: 0.72-1.36, P ¼ 0.906 by log-rank test) (Figure 2A ). The secondary end point of OS showed no difference between patients receiving the CetCis versus CetCisPac regimen (median: 13 versus 11 months, respectively; HR ¼ 0.77; 95% CI: 0.53-1.11, P ¼ 0.117 by log-rank test) ( Figure 2B ). The secondary objective of ORR was 41.8% in the CetCis arm and 51.7% in the CetCisPac arm (OR ¼ 0.67; 95% CI: 0.38-1.20, P ¼ 0.181 by Cochran-Mantel-Haenszel test; Table 2 ).
Safety
Within the ITT population of the B490 study, 99 patients (99.0%) in the CetCis arm and 91 patients (100%) in the CetCisPac arm had an adverse event (AE) of any grade (Table S1 ). Additionally, 76 (76.0%) and 66 (72.5%) patients in the CetCis and CetCisPac regimen, respectively, experienced a grade 3 AE. Grade 4 toxicities were reported in 14% of patients receiving CetCis and 33% of those receiving CetCisPac (P ¼ 0.015 by Pearson's v 2 test). Detailed incidences of grade 3 events can be found in Table 3 . Of note, no sepsis occurred and cardiac events were negligible (1%). No treatment-related deaths were observed in either arm.
Discussion
The B490 study showed that the CetCis regimen was noninferior to the CetCisPac regimen in terms of PFS. Importantly, although the ORR and OS yielded by the two regimens were not statistically significantly different, the ORR achieved by the CetCisPac regimen was >50%. The EXTREME trial (CetCis plus 5-FU) accomplished an ORR of 36% [4] . Indeed, it is quite remarkable that in our trial, even the two-agent regimen (CetCis) yielded a response rate comparable to that observed with the EXTREME regimen. It is possible, therefore, that 5-FU may not add significant efficacy benefits to patients when combined with cetuximab plus cisplatin.
Alternatively, patient selection may have played a role in improving the ORR found in this study. Notably, the B490 and EXTREME studies used identical inclusion and exclusion criteria, with the single exception that our study also permitted enrollment of patients who had previously received cetuximab in the locoregionally advanced setting (6%). Furthermore, it appears that the patient populations of the two trials were somewhat distinct [age favored the EXTREME trial (median age of 63 and 62 years in the CetCis and CetCisPac treatment arms, respectively, versus 56 years in EXTREME), whereas PS favored B490 (12% in EXTREME had an ECOG PS 2, while B490 enrolled only 
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Annals of Oncology patients with a PS of 0 or 1)]. Finally, the proportion of patients with HPV-positive disease was low in both trials. It is therefore difficult to conclude whether one study population had an overall worse prognosis at baseline.
Another factor that may have affected patient selection is geography. Specifically, B490 was conducted in Italy alone, whereas EXTREME was multinational. Based on learnings from the SPECTRUM trial, the addition of panitumumab to platinumbased chemotherapy was effective in some countries (Western ones) but not at the global level [27] .
Nevertheless, an ORR of 51.7% is very encouraging for a first-line treatment of patients with R/M SCCHN. Apart from the EXTREME regimen, analogous first-line regimens utilizing cetuximab, a platinum agent, and a taxane have thus far yielded ORRs of 37.8% in the phase 2 CSPOR-HN02 trial of the PCE regimen (cetuximab, carboplatin, paclitaxel) [13] and 51.9% in the TPEx trial (cetuximab, cisplatin, docetaxel) [20] . Furthermore, these studies have consistently found a slightly higher ORR with a taxane in combination with cetuximab/platinum over 5-FU. However, as mentioned earlier, a phase 3 trial should be completed to confirm these findings.
Additionally, in the current study, the safety profile of CetCisPac was not as favorable as that of the CetCis regimen but still appears to have been more favorable-in terms of the incidence of life-threatening toxicities-than that observed with the EXTREME regimen [4, 20] . Indeed, by substituting 5-FU for paclitaxel, the rates of grade 3 cardiac toxicity appeared lower (1.0% with either CetCis or CetCisPac versus 7% with the EXTREME regimen [4] ), consistent with the established cardiac toxicity induced by 5-FU [14, 28] . Furthermore, the rate of grade 3 febrile neutropenia was similar between CetCisPac and the EXTREME regimen (6.6% and 5%, respectively) [4] and lower with CetCis (1.0%). While Vermorken et al. reported an incidence of sepsis of 4% [4] , we observed no cases of sepsis in either arm of B490. Although Vermorken et al. did not present the rates of infection/fever, the rates of grade 3 infection/fever were manageable with both CetCisPac (8.8%) and CetCis (2.0%). Additionally, the proportion of grade 4 toxicities with CetCis was only 14% compared with 33% with the CetCisPac combination and 31% with the EXTREME regimen [4] . Overall, for this frail patient population, CetCisPac and, even more so, CetCis may be milder systemic regimens than the EXTREME one, which is associated with more life-threatening toxic events. Finally, in the EXTREME study, the three-drug regimen (cetuximab, cisplatin, and 5-FU) improved some quality of life (QoL) items and did not result in any overall deterioration of QoL scores [29] . Therefore, if the CetCisPac drug combination is indeed more efficacious than the EXTREME regimen, but does not confer the 5-FU-associated toxicities, we suggest that the adverse impact on QoL might be even smaller with this therapy. Furthermore, as advances in the immunotherapy field progress, CetCisPac and CetCis may represent more favorable combination therapy backbones than cetuximab plus cisplatin plus 5-FU [4, 20, 30] .
Several limitations of this study exist that could be addressed in future studies. First, as described above, outcomes with the firstline regimens tested in B490 cannot be directly compared with those with the EXTREME regimen because of the absence of a head-to-head comparator arm. However, such a comparison may not be strictly necessary, because the use of taxanes is already widespread in clinical practice, and physicians are comfortable with this approach in R/M SCCHN. Additionally, although the higher ORR observed in B490 suggests that more patients experienced tumor shrinkage and, therefore, likely an improvement in QoL, we did not prospectively perform such an analysis. Finally, it would be interesting to confirm the findings of this study in a larger patient cohort, either in a phase 3 clinical trial or a noninterventional, real-world study. In summary, here we demonstrate that when aiming to achieve maximal clinical response for R/M SCCHN, cetuximab and cisplatin plus paclitaxel may be a highly active regimen. We suggest that substitution of paclitaxel in place of 5-FU may yield a higher probability of response while also improving tolerability when combined with cetuximab plus cisplatin. Indeed, we emphasize the importance of striving for a balance between tolerability and activity when selecting the appropriate first-line regimen for patients with R/M SCCHN. In this regard, a CetCis schedule offers a valid option without impacting PFS.
Conclusion
Here we present the results of a randomized, phase 2 noninferiority study that compared first-line treatment of patients with R/M SCCHN with cetuximab plus cisplatin with or without paclitaxel.
Importantly, this was the first study to conduct a comparison of two different, cetuximab-based approaches in the first-line R/M SCCHN setting, with neither being the standard-of-care comparator. Through an indirect comparison with the EXTREME study, we suggest that substituting paclitaxel instead of 5-FU in the EXTREME regimen results in similar survival, a 15% increase in the ORR, and a more favorable safety profile (including, importantly, reduced cardiac toxicity). Finally, the noninferiority of CetCis to CetCisPac is of value as both regimens are currently administered in clinical practice, leveraging their different safety profiles. Finally, both may be more amenable combination partner versus the EXTREME regimen and therefore could represent potential backbones for combinations with new and emerging immunotherapies, such as checkpoint inhibitors.
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